AFJOG

Bayer is the Global Number 1 1 Women’s Healthcare company: Answering a woman’s needs in different stages of her life. Bayer is committed to provide access to 2 : Modern contraception to 100 million women by 2030 Essential vitamins and minerals to 4 million pregnant women and their unborn babies 3 each year • • By 2030, the population of women who will experience menopause will be: • 1.2 billion worldwide with • 47 million women with menopause each year 1. Source: IQVIA Feb 2023; Rx market comprising contraception, menopause management & gynecological therapies 2. in low- and middle-income countries 3. in partnership with Vitamin Angels B BAYER 68/011192/07. Scan the QR code for the MAH/HCR address. Tel. +27 (0)11 921 500 Bayer (Pty) Ltd. Reg. No.: 1968/011192/07. Scan the QR code for the MAH/HCR address. Tel. +27 (0)11 921 5000 . PP-PF-WHC-ZA-0125-1 Mirena’ plus Qlaira S4 Kyleena ® Levonorgestrel intrauterine system. Each sterile intrauterine system contains levonorgestrel 19.5 mg. RSA Reg. No.: 47 /32.9/0037. Namibia: NS2 Reg. No.: 23/32.9/0012. S4 Mirena ® Levonorgestrel intrauterine system. Each sterile intrauterine system contains levonorgestrel 52 mg, 20 µg/24hrs. Indication: Contraception. Idiopathic Menorrhagia. Protection from endometrial hyperplasia during estrogen replacement therapy. RSA Reg. No.: 32/34/0332. Namibia: NS2 Reg. No.: 04/34/1017. Botswana: (S2) Reg. No.: BOT0700957. Mauritius: Reg. No.: R9846/02/14. Zimbabwe: Reg. No.: 2022/21.2/6268. S3 Qlaira ® Tablets. The 28- day pack contains 2 dark yellow tablets each containing 3 mg estradiol valerate and 5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest and 17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest and 2 dark red tablets each containing 1 mg estradiol valerate and 2 white placebo tablets. RSA Reg. No.: 43/18.8/0591. Mauritius: Reg. No.: R9050/02/14. Namibia: NS2 Reg. No.: 13/21.8.2/0154. S4 Angeliq ® Tablets. The pack contains 28 hormonal red film-coated tablets each with estradiol hemihydrate 1.033 mg (equivalent to estradiol 1.0 mg) and drospirenone 2.0 mg. RSA Reg. No.: 37/21.8.2/0451. Botswana: (S2) Reg. No.: BOT0901586. Mauritius: Reg. No.: PB/13134/07/2019. Namibia: NS2 Reg. No.: 04/21.8.2/1466. S4 Yaz ® Plus Tablets. The 28-day pack contains 24 hormone-containing pink film-coated tablets each with 3 mg drospirenone, 0.02 mg ethinylestradiol (as betadex clathrate) and 0.451 mg levomefolate calcium (equimolar to 0.400 mg folic acid), plus 4 hormone-free light orange film-coated tablets each with 0.451 mg levomefolate calcium. RSA Reg. No.: 45/21.8.2/0534. Mauritius: Reg. No.: E13025/05/2018. Namibia: NS2 Reg. No.: 20/18.7/0135. Zimbabwe: (PP) Reg. No.: 2022/21.2.1/6235. Botswana: (S2) Reg. No.: BOT2304014. S4 Yasmin ® Plus Tablets. The 28-day pack contains 21 hormone-containing orange film-coated tablets each with 3 mg drospirenone, 0.03 mg ethinylestradiol (as betadex clathrate) and 0.451 mg levomefolate calcium (equimolar to 0.400 mg folic acid), plus 7 hormone-free light orange film-coated tablets each with 0.451 mg levomefolate calcium. RSA Reg. No.: 45/18.8/0535. Mauritius: Reg. No.: E13026/05/2018. Namibia: NS2 Reg. No.: 20/18.7/0134. Zimbabwe: (PP) Reg. No.: 2022/21.2.1/6234. Botswana: (S2) Reg. No.: BOT2304015. S3 Visanne ® Tablets. Each tablet contains 2 mg dienogest. RSA Reg. No.: 44/21.8.2/0159.Mauritius: Reg. No.: PB/12884/05/2017. Namibia: NS2 Reg. No.: 13/21.8.2/0230.Zimbabwe: (PP) Reg. No.: 2017/21.8/5493. Malawi: Reg. No.: PMPB/PL16/16. For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority.